Medicinal mushrooms have been used in traditional medicine for centuries and are now sold worldwide as supplements. Reishi is sold for calm and immunity. Chaga is sold for almost everything. Much of the scientific interest in both comes down to one family of compounds: triterpenes.
In the lab, mushroom triterpenes do remarkable things. They slow cancer cells, block enzymes linked to hair loss and cholesterol, and calm inflammatory immune cells. The harder question is what happens when a person swallows them. This article explains what triterpenes are, what they do outside medicine, why reishi and chaga are the two mushrooms to watch, what they contain, what human trials have actually found, and what to watch for on safety and labels.
What are triterpenes?
Triterpenes are terpenes built from six isoprene units, giving them a 30-carbon skeleton[1]. That makes them much larger than the monoterpenes (10 carbons) and sesquiterpenes (15 carbons) that give cannabis its smell. Their size makes them far less volatile than the smaller terpenes responsible for aroma, so they generally contribute little to smell. When a terpene carries oxygen, for example as an alcohol or an acid, chemists call it a terpenoid; most of the compounds in this article are, strictly speaking, triterpenoids. Our guide to the language behind terpenes and terpenoids explains the naming, and our complete guide to terpenes covers the smaller ones.
Triterpenes are also close chemical relatives of sterols. Plants, animals and fungi all build their sterols, including cholesterol in people and ergosterol in fungi, from the same 30-carbon starting material. Many mushroom triterpenes are lanostanes, named after lanosterol, the shared step on the way to those sterols[1].
Lanostane, the 30-carbon skeleton behind many mushroom triterpenes. Image: Edgar181, via Wikimedia Commons, public domain.
Do triterpenes do anything besides medicine?
Yes. Mushrooms don’t make triterpenes for our benefit. Like the smaller terpenes in cannabis, they are secondary metabolites, compounds the organism doesn’t need for basic growth but that help it deal with the world around it. What they do inside the mushroom is much less studied than what they do to human cells, but there are clues.
One is taste. Some of the first triterpenoids chemists isolated from Ganoderma mushrooms were described simply as bitter compounds[2], and that bitterness is part of why reishi is usually taken as a tea, tincture or capsule rather than eaten. Another is defense against microbes. In the mold Aspergillus fumigatus, the triterpenoid helvolic acid works as an antibiotic, and researchers think it may help the fungus shape the bacteria and other microbes it competes with in soil[3].
Outside the fungal world, triterpenes are already part of everyday life. Glycyrrhizin, the sweet compound in licorice root, is a triterpenoid saponin at least 30 times sweeter than sugar and is widely used as a sweetener and flavoring[4]. And as the chaga section below shows, the triterpenes in birch bark have become a licensed wound medicine.
Why focus on reishi and chaga?
Many mushrooms make triterpenes, as the king trumpet example later in this article shows. But two stand out when it comes to these compounds specifically.
Reishi is the most thoroughly studied triterpene mushroom. A 2023 review catalogued 495 compounds from 25 Ganoderma species published since 1984, and described triterpenes as the genus’s primary components[5]. It is also the only mushroom discussed here that has been evaluated in Cochrane reviews.
Chaga is the other mushroom whose reputation rests heavily on triterpenes, in its case betulin and betulinic acid, the same compounds found in birch bark[6]. That makes it the natural test of whether a famous triterpene source holds up in people.
Several other best-selling “functional” mushrooms are sold for different compounds altogether. Lion’s mane, for example, is marketed for compounds that aren’t triterpenes, as explained below. So reishi and chaga are where the triterpene story can actually be tested.
What triterpenes are in reishi?
Reishi, or lingzhi, is a shiny, reddish shelf fungus in the genus Ganoderma. Its signature triterpenes are the ganoderic acids, lanostane-type compounds with a bitter taste.
Ganoderic acid A, one of reishi’s signature triterpenes. Image: Edgar181, via Wikimedia Commons, public domain.
The name on the label is often out of date. For decades, the reishi grown in East Asia was called Ganoderma lucidum, a species originally described from Europe. Genetic work showed the cultivated Asian mushroom is a different species. It was named Ganoderma lingzhi in 2012[7], and a 2023 re-examination of the original specimens concluded that the cultivated mushroom should be called Ganoderma sichuanense, with G. lingzhi treated as a later synonym[8]. Most studies and products still use G. lucidum, and many continue to use G. lingzhi.
In laboratory studies, reishi triterpenes inhibit several enzymes with drug-like targets:
- 5α-reductase. Some ganoderic acids block this enzyme, which converts testosterone to the more potent dihydrotestosterone and is the target of prostate and hair-loss drugs[9].
- HMG-CoA reductase and α-glucosidase. Some, but not all, lanostanes from reishi inhibit the cholesterol-making enzyme that statins target, and an enzyme that diabetes drugs block to slow sugar absorption[10].
These are test-tube findings. They show that the molecules can interact with these enzymes, not that a reishi supplement lowers cholesterol or regrows hair.
What do human trials of reishi show?
Cancer. A 2016 Cochrane review pooled five randomized trials with 373 people, all in China[11]. When reishi was added to chemotherapy or radiotherapy, tumors were more likely to respond, but the result was not statistically conclusive (relative risk 1.50, 95% confidence interval 0.90 to 2.51). Reishi alone did not shrink tumors. Immune-cell counts rose slightly, and four studies reported better quality of life. No trial measured long-term survival. The reviewers judged the trials to be of generally poor quality and concluded that reishi is not supported as a first-line cancer treatment, though it might be considered alongside standard care[11].
Blood sugar, blood pressure and cholesterol. A 2015 Cochrane review found three usable trials with 157 people with type 2 diabetes[12]. Reishi did not significantly lower HbA1c, fasting glucose, blood pressure or cholesterol. The authors concluded that the evidence does not support reishi for cardiovascular risk factors[12].
Neither review tested purified triterpenes. Most trials used whole extracts or polysaccharide-rich preparations, so they can’t say which compounds did, or didn’t, do the work.
What triterpenes are in chaga?
Chaga (Inonotus obliquus) isn’t a typical mushroom at all. The material harvested as chaga is not the fungus’s conventional fruiting body. It is a black, cracked, sterile conk that forms mostly on living birch trees. Its triterpenes include betulin and betulinic acid, the same compounds found in birch bark[13], plus lanostane triterpenes of its own[6].
In laboratory studies, chaga triterpenoids have shown anti-inflammatory activity; one, betulin-3-O-caffeate, reduced nitric oxide production by immune cells[6]. Betulin and betulinic acid have also slowed cancer cell lines in vitro, as Lance Griffin described in the original version of this article.
Betulin does have one genuine medical success, but it doesn’t come from chaga. Filsuvez, a gel made from silver and downy birch bark extract, was approved in the European Union in June 2022 and by the US Food and Drug Administration in December 2023 for wounds in the rare blistering skin disease epidermolysis bullosa[13, 14]. Its active ingredients are birch triterpenes, including betulin, betulinic acid and lupeol[13]. That approval says nothing about drinking chaga tea, but it shows that this family of compounds can become real medicine when it is purified, dosed and tested.
Betulin, the birch-bark triterpene that chaga also contains. Image: V8rik, via Wikimedia Commons, CC BY-SA 3.0.
Has chaga been tested in people?
Barely. A review of human clinical trials of popular medicinal mushrooms found only two human studies of chaga, both from the Soviet Union in the 1970s and early 1980s, in psoriasis and peptic ulcer patients[15]. Both used Befungin, a Soviet chaga preparation that also contained cobalt salts, so neither was a straightforward test of a modern chaga supplement, and neither was randomized, controlled or blinded[15]. That review searched only through April 2015. Our own searches in November 2026 found no published randomized controlled trial showing that chaga alone benefits people. Its reputation still rests largely on tradition, cell studies and animal studies.
What about other mushrooms?
Triterpenes turn up across the fungal kingdom. Lance Griffin’s original article highlighted king trumpet (Pleurotus eryngii), from which researchers isolated three triterpenes, including lupeol and two new compounds, that slowed the growth of breast cancer cells in the lab[16].
Two of the most popular supplement mushrooms are sold for other compounds. Lion’s mane is marketed for the brain on the strength of erinacines, which are diterpenoids found in the mycelium, and hericenones, which are meroterpenoids found in the fruiting body[17]. Neither is a triterpene. For more on brain-focused supplements, see our article on nootropics.
Mushroom triterpenes at a glance
| Mushroom | Key triterpenes | Strongest evidence | Human trials? | Main safety note |
|---|---|---|---|---|
| Reishi (Ganoderma) | Ganoderic acids and other lanostanes | Two Cochrane reviews of small trials | Yes, small and mostly low quality | Rare liver injury; may increase bleeding risk |
| Chaga (Inonotus obliquus) | Betulin, betulinic acid, lanostanes | Cell and animal studies | No controlled trials | Very high oxalate; kidney damage reported |
| King trumpet (Pleurotus eryngii) | Lupeol and related triterpenes | Cell studies | No | A common food mushroom |
| Lion’s mane (Hericium erinaceus) | Not sold for triterpenes (erinacines are diterpenoids) | Preclinical studies of erinacines | Not covered here | Not covered here |
Why don’t lab results translate into supplements?
Because a cell in a dish and a person taking a capsule are very different situations.
Not much reaches the blood, and not for long. In a study of 12 healthy men given 3 g of a reishi water extract, ganoderic acid A peaked in the blood about 30 minutes later at roughly 11 nanograms per milliliter, and its half-life was only about 37 minutes[18]. Taking it with food lowered and delayed the peak, and for ganoderic acid F, food blocked absorption so much that levels were mostly too low to measure[18]. Lab studies often bathe cells in far more for far longer.
The extraction method decides what’s in the jar. Triterpenes dissolve poorly in water, while the mushroom’s polysaccharides, such as beta-glucans, are extracted with hot water. That is why many products describe themselves as “dual extracts”, using both water and alcohol. The label should tell you which compounds the product is standardized to, and how much.
Mycelium and fruiting body are not interchangeable. Some products are made by growing mycelium, the thread-like body of the fungus, on cereal grain and harvesting the colonized grain with it. Testing has shown that much of the grain’s starch can remain intact in these products[19]. A high “total glucan” or “polysaccharide” number therefore doesn’t necessarily mean a high fungal beta-glucan content; alpha-glucans (starch) and beta-glucans should be reported separately[19]. The fruiting body is the part of the mushroom you can see; our mushroom anatomy poster shows the difference.
Are reishi and chaga safe?
For most people in the short term, reishi appears well tolerated, but both mushrooms have documented risks.
Chaga and the kidneys. Chaga is extremely high in oxalate, the same compound that forms most kidney stones. In a Korean case, a 49-year-old man took chaga powder for about five years for eczema, 3 g a day and then 9 g a day. His kidneys failed, and a biopsy showed calcium oxalate crystals. The leftover powder contained 14.2 g of oxalate per 100 g, and he remained on dialysis 18 months later[20]. In another case, a 69-year-old man who took 10 to 15 g a day for about three months, along with vitamin C, developed acute kidney injury; he needed dialysis and steroids but recovered[21]. An earlier case of chaga-related kidney failure was reported in Japan in 2014[20]. People with kidney disease or a history of kidney stones should avoid chaga.
Reishi and the liver. The US government’s LiverTox database rates reishi as a possible rare cause of liver injury. A small number of case reports describe hepatitis, usually starting one to two months after people began taking it, and one fatal case in Thailand involved acute liver failure in a person taking reishi powder[22]. Most people recovered within one to three months of stopping, and many reports could not rule out other causes[22]. A 2023 case involved acute liver injury in a man who took several tablespoons of reishi powder alongside heavy drinking[23].
Drug interactions. Memorial Sloan Kettering advises that reishi may increase bleeding risk with blood thinners such as warfarin, and may not be safe for people taking immunosuppressants[24]. Reishi spore powder may also raise the tumor marker CA72-4, which could confuse cancer test results[24].
Because safety in pregnancy hasn’t been established, and because of the bleeding concern, anyone scheduled for surgery should ask their clinician whether and when to stop taking them, and it is sensible to avoid them when pregnant or breastfeeding unless a doctor advises otherwise. Anyone with a medical condition or on prescription medication should talk to a doctor first.
How do you read a mushroom supplement label?
- Look for the species and the material used. If you are buying reishi specifically for triterpenes, the fruiting body is generally the relevant material; for chaga, it is the sterile conk. “Fruiting body” and “mycelium” are not interchangeable. If the label says “myceliated grain,” expect some substrate-derived starch[19]. If it says only “mycelium,” look for information about the growth medium and compare the reported alpha- and beta-glucan levels.
- Look for the extraction. Water extracts are rich in polysaccharides. If you want triterpenes, the label should say alcohol or dual extraction.
- Look for numbers, not adjectives. A good label states the percentage of beta-glucans, reported separately from starch. For reishi, look for quantified ganoderic acids or a triterpene result that identifies the testing method; a generic “total triterpenes” percentage is less informative, because different assays may measure different collections of compounds. “Full spectrum” and “super potent” are not measurements.
- Look for testing. A certificate of analysis from an independent lab should confirm the claimed contents and check for heavy metals.
Product testing shows why that matters. When researchers analyzed 19 reishi supplements bought in the United States, using triterpene fingerprints and polysaccharide mapping, only five, or 26%, were consistent with their labels[25]. Triterpenes resembling those of authenticated reishi turned up in only eight of the 19, and 13 contained starch-like fillers that aren’t found in the fruiting body[25].
Mushrooms and cannabis are increasingly sold side by side; our article on the marriage of cannabis and mushrooms explores that crossover.
The short version
Mushroom triterpenes are real, potent and chemically fascinating. Reishi’s ganoderic acids and chaga’s betulin compounds act on enzymes and immune cells in ways that interest drug researchers, and birch-bark betulin has already become an approved medicine. But the human evidence for the mushrooms themselves is thin: small, low-quality trials for reishi and essentially none for chaga. Triterpenes are poorly absorbed and quickly cleared, and in one test of US reishi supplements, only about a quarter matched their labels[25]. If you take reishi or chaga, choose a tested product that clearly identifies the species, fungal material and extraction method (fruiting body for reishi, sterile conk for chaga), keep doses modest, avoid chaga if you have kidney problems, and tell your doctor, especially if you take blood thinners.
References
- Breitmaier E. Triterpenes. In: Terpenes. Wiley-VCH; 2006:86.
- Nishitoba T, et al. Bitter triterpenoids from the fungus Ganoderma applanatum. Phytochemistry. 1989;28(1):193-197.
- Boysen JM, Saeed N, Hillmann F. Natural products in the predatory defence of the filamentous fungal pathogen Aspergillus fumigatus. Beilstein J Org Chem. 2021;17.
- Graebin CS. The pharmacological activities of glycyrrhizinic acid (“glycyrrhizin”) and glycyrrhetinic acid. In: Mérillon JM, Ramawat KG, eds. Sweeteners. Springer; 2018.
- Galappaththi MCA, Patabendige NM, Premarathne BM, et al. A review of Ganoderma triterpenoids and their bioactivities. Biomolecules. 2023;13(1):24.
- Wold CW, et al. Bioactive triterpenoids and water-soluble melanin from Inonotus obliquus (Chaga) with immunomodulatory activity. J Funct Foods. 2020;71:104025.
- Cao Y, Wu SH, Dai YC. Species clarification of the prize medicinal Ganoderma mushroom “Lingzhi”. Fungal Divers. 2012;56(1):49-62.
- Du Z, Li Y, Wang XC, et al. Re-examination of the holotype of Ganoderma sichuanense (Ganodermataceae, Polyporales) and a clarification of the identity of Chinese cultivated Lingzhi. J Fungi. 2023;9(3):323.
- Liu J, et al. Structure-activity relationship for inhibition of 5α-reductase by triterpenoids isolated from Ganoderma lucidum. Bioorg Med Chem. 2006;14(24):8654-8660.
- Chen B, et al. Triterpenes and meroterpenes from Ganoderma lucidum with inhibitory activity against HMG-CoA reductase, aldose reductase and α-glucosidase. Fitoterapia. 2017;120:6-16.
- Jin X, Ruiz Beguerie J, Sze DM, Chan GCF. Ganoderma lucidum (Reishi mushroom) for cancer treatment. Cochrane Database Syst Rev. 2016;(4):CD007731.
- Klupp NL, Chang D, Hawke F, et al. Ganoderma lucidum mushroom for the treatment of cardiovascular risk factors. Cochrane Database Syst Rev. 2015;(2):CD007259.
- US Food and Drug Administration. Novel drug approvals for 2023: Filsuvez (birch triterpenes) topical gel. FDA; December 2023.
- European Medicines Agency. Filsuvez (birch bark extract): European public assessment report. EMA; 2022.
- Frost M. Three popular medicinal mushroom supplements: a review of human clinical trials. Brigham Young University ScholarsArchive, Faculty Publications 1609.
- Xue Z, et al. Triterpene from Pleurotus eryngii with inhibitory effects against breast cancer. Plant Foods Hum Nutr. 2015;70:291-296.
- Spangenberg ET, Moneypenny A, Bozzo GG, et al. Unveiling the role of erinacines in the neuroprotective effects of Hericium erinaceus: a systematic review in preclinical models. Front Pharmacol. 2025;16:1582081.
- Teekachunhatean S, Sadja S, Ampasavate C, et al. Pharmacokinetics of ganoderic acids A and F after oral administration of Ling Zhi preparation in healthy male volunteers. Evid Based Complement Alternat Med. 2012;2012:780892.
- McCleary BV, Draga A. Measurement of β-glucan in mushrooms and mycelial products. J AOAC Int. 2016;99(2):364-373.
- Lee S, Lee HY, Park Y, et al. Development of end stage renal disease after long-term ingestion of chaga mushroom: case report and review of literature. J Korean Med Sci. 2020;35(19):e122.
- Kwon O, Kim Y, Paek JH, et al. Chaga mushroom-induced oxalate nephropathy that clinically manifested as nephrotic syndrome: a case report. Medicine (Baltimore). 2022;101(10):e28997.
- National Institute of Diabetes and Digestive and Kidney Diseases. Lingzhi, Reishi. In: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Updated 5 October 2024.
- Guedikian R, Kim B, Singh G. Ganoderma lingzhi (reishi mushroom)-induced acute liver injury in the setting of alcohol use: a case report and review of the literature. Cureus. 2023;15(9):e45953.
- Memorial Sloan Kettering Cancer Center. Reishi mushroom. About Herbs, Botanicals and Other Products. Updated 5 May 2026.
- Wu DT, Deng Y, Chen LX, et al. Evaluation on quality consistency of Ganoderma lucidum dietary supplements collected in the United States. Sci Rep. 2017;7:7792.
This article is an educational summary of published research. It is not medical advice. Talk to a doctor before taking mushroom supplements, especially if you have kidney or liver disease or take prescription medicines.
Editor’s note: Originally published November 2020 by Lance Griffin; rewritten and updated November 2026 with human trial evidence, pharmacokinetics and safety data
Photo: RevDanielElisAxelrod, CC0, via Wikimedia Commons
Last updated: November 2026.




